Cargando…

Early treatment response to piperacillin/tazobactam in patients with bloodstream infections caused by non-ESBL ampicillin/sulbactam-resistant Escherichia coli: a binational cohort study

PURPOSE: This study aimed to compare treatment outcomes for bloodstream infections (BSI) caused by a piperacillin/tazobactam (PIP/TAZ)-susceptible E. coli among three patient groups: BSI caused by ampicillin/sulbactam (AMP/SLB)-resistant isolates treated with PIP/TAZ, BSI caused by AMP/SLB-sensitive...

Descripción completa

Detalles Bibliográficos
Autores principales: Tobudic, Selma, Bahrs, Christina, Schneider, Lisa, Paulussen, Emilia, Bartonickova, Lucie, Hagel, Stefan, Starzengruber, Peter, Burgmann, Heinz, Pletz, Mathias W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665230/
https://www.ncbi.nlm.nih.gov/pubmed/37462895
http://dx.doi.org/10.1007/s15010-023-02074-z
_version_ 1785138783515049984
author Tobudic, Selma
Bahrs, Christina
Schneider, Lisa
Paulussen, Emilia
Bartonickova, Lucie
Hagel, Stefan
Starzengruber, Peter
Burgmann, Heinz
Pletz, Mathias W.
author_facet Tobudic, Selma
Bahrs, Christina
Schneider, Lisa
Paulussen, Emilia
Bartonickova, Lucie
Hagel, Stefan
Starzengruber, Peter
Burgmann, Heinz
Pletz, Mathias W.
author_sort Tobudic, Selma
collection PubMed
description PURPOSE: This study aimed to compare treatment outcomes for bloodstream infections (BSI) caused by a piperacillin/tazobactam (PIP/TAZ)-susceptible E. coli among three patient groups: BSI caused by ampicillin/sulbactam (AMP/SLB)-resistant isolates treated with PIP/TAZ, BSI caused by AMP/SLB-sensitive isolates treated with PIP/TAZ, and BSI caused by AMP/SLB-resistant isolates treated with another monotherapy. METHODS: This retrospective study was conducted in two academic centres in Europe. Adult patients with E. coli BSI were screened from 2014 to 2020. Inclusion criteria were non-ESBL BSI and initial monotherapy for ≥ 72 h. To reduce the expected bias between the patient groups, propensity score matching was performed. The primary outcome was early treatment response after 72 h and required absence of SOFA score increase in ICU/IMC patients, as well as resolution of fever, leukocytosis, and bacteraemia. RESULTS: Of the 1707 patients screened, 315 (18.5%) were included in the final analysis. Urinary tract infection was the most common source of BSI (54.9%). Monotherapies other than PIP/TAZ were cephalosporins (48.6%), carbapenems (34.3%), and quinolones (17.1%). Enhanced early treatment response rate was detected (p = 0.04) in patients with BSI caused by AMP/SLB-resistant isolates treated with another monotherapy (74.3%) compared to those treated with PIP/TAZ (57.1%), and was mainly driven by the use of cephalosporins and quinolones (p ≤ 0.03). Clinical success, 28-day mortality, and rate of relapsing BSI did not significantly differ between the groups. CONCLUSIONS: Our study suggests that initial use of PIP/TAZ may be associated with reduced early treatment response in E. coli BSI caused by AMP/SLB-resistant isolates compared to alternative monotherapies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s15010-023-02074-z.
format Online
Article
Text
id pubmed-10665230
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-106652302023-07-18 Early treatment response to piperacillin/tazobactam in patients with bloodstream infections caused by non-ESBL ampicillin/sulbactam-resistant Escherichia coli: a binational cohort study Tobudic, Selma Bahrs, Christina Schneider, Lisa Paulussen, Emilia Bartonickova, Lucie Hagel, Stefan Starzengruber, Peter Burgmann, Heinz Pletz, Mathias W. Infection Research PURPOSE: This study aimed to compare treatment outcomes for bloodstream infections (BSI) caused by a piperacillin/tazobactam (PIP/TAZ)-susceptible E. coli among three patient groups: BSI caused by ampicillin/sulbactam (AMP/SLB)-resistant isolates treated with PIP/TAZ, BSI caused by AMP/SLB-sensitive isolates treated with PIP/TAZ, and BSI caused by AMP/SLB-resistant isolates treated with another monotherapy. METHODS: This retrospective study was conducted in two academic centres in Europe. Adult patients with E. coli BSI were screened from 2014 to 2020. Inclusion criteria were non-ESBL BSI and initial monotherapy for ≥ 72 h. To reduce the expected bias between the patient groups, propensity score matching was performed. The primary outcome was early treatment response after 72 h and required absence of SOFA score increase in ICU/IMC patients, as well as resolution of fever, leukocytosis, and bacteraemia. RESULTS: Of the 1707 patients screened, 315 (18.5%) were included in the final analysis. Urinary tract infection was the most common source of BSI (54.9%). Monotherapies other than PIP/TAZ were cephalosporins (48.6%), carbapenems (34.3%), and quinolones (17.1%). Enhanced early treatment response rate was detected (p = 0.04) in patients with BSI caused by AMP/SLB-resistant isolates treated with another monotherapy (74.3%) compared to those treated with PIP/TAZ (57.1%), and was mainly driven by the use of cephalosporins and quinolones (p ≤ 0.03). Clinical success, 28-day mortality, and rate of relapsing BSI did not significantly differ between the groups. CONCLUSIONS: Our study suggests that initial use of PIP/TAZ may be associated with reduced early treatment response in E. coli BSI caused by AMP/SLB-resistant isolates compared to alternative monotherapies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s15010-023-02074-z. Springer Berlin Heidelberg 2023-07-18 2023 /pmc/articles/PMC10665230/ /pubmed/37462895 http://dx.doi.org/10.1007/s15010-023-02074-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Tobudic, Selma
Bahrs, Christina
Schneider, Lisa
Paulussen, Emilia
Bartonickova, Lucie
Hagel, Stefan
Starzengruber, Peter
Burgmann, Heinz
Pletz, Mathias W.
Early treatment response to piperacillin/tazobactam in patients with bloodstream infections caused by non-ESBL ampicillin/sulbactam-resistant Escherichia coli: a binational cohort study
title Early treatment response to piperacillin/tazobactam in patients with bloodstream infections caused by non-ESBL ampicillin/sulbactam-resistant Escherichia coli: a binational cohort study
title_full Early treatment response to piperacillin/tazobactam in patients with bloodstream infections caused by non-ESBL ampicillin/sulbactam-resistant Escherichia coli: a binational cohort study
title_fullStr Early treatment response to piperacillin/tazobactam in patients with bloodstream infections caused by non-ESBL ampicillin/sulbactam-resistant Escherichia coli: a binational cohort study
title_full_unstemmed Early treatment response to piperacillin/tazobactam in patients with bloodstream infections caused by non-ESBL ampicillin/sulbactam-resistant Escherichia coli: a binational cohort study
title_short Early treatment response to piperacillin/tazobactam in patients with bloodstream infections caused by non-ESBL ampicillin/sulbactam-resistant Escherichia coli: a binational cohort study
title_sort early treatment response to piperacillin/tazobactam in patients with bloodstream infections caused by non-esbl ampicillin/sulbactam-resistant escherichia coli: a binational cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665230/
https://www.ncbi.nlm.nih.gov/pubmed/37462895
http://dx.doi.org/10.1007/s15010-023-02074-z
work_keys_str_mv AT tobudicselma earlytreatmentresponsetopiperacillintazobactaminpatientswithbloodstreaminfectionscausedbynonesblampicillinsulbactamresistantescherichiacoliabinationalcohortstudy
AT bahrschristina earlytreatmentresponsetopiperacillintazobactaminpatientswithbloodstreaminfectionscausedbynonesblampicillinsulbactamresistantescherichiacoliabinationalcohortstudy
AT schneiderlisa earlytreatmentresponsetopiperacillintazobactaminpatientswithbloodstreaminfectionscausedbynonesblampicillinsulbactamresistantescherichiacoliabinationalcohortstudy
AT paulussenemilia earlytreatmentresponsetopiperacillintazobactaminpatientswithbloodstreaminfectionscausedbynonesblampicillinsulbactamresistantescherichiacoliabinationalcohortstudy
AT bartonickovalucie earlytreatmentresponsetopiperacillintazobactaminpatientswithbloodstreaminfectionscausedbynonesblampicillinsulbactamresistantescherichiacoliabinationalcohortstudy
AT hagelstefan earlytreatmentresponsetopiperacillintazobactaminpatientswithbloodstreaminfectionscausedbynonesblampicillinsulbactamresistantescherichiacoliabinationalcohortstudy
AT starzengruberpeter earlytreatmentresponsetopiperacillintazobactaminpatientswithbloodstreaminfectionscausedbynonesblampicillinsulbactamresistantescherichiacoliabinationalcohortstudy
AT burgmannheinz earlytreatmentresponsetopiperacillintazobactaminpatientswithbloodstreaminfectionscausedbynonesblampicillinsulbactamresistantescherichiacoliabinationalcohortstudy
AT pletzmathiasw earlytreatmentresponsetopiperacillintazobactaminpatientswithbloodstreaminfectionscausedbynonesblampicillinsulbactamresistantescherichiacoliabinationalcohortstudy